1 |
Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey[J]. Am J Respir Crit Care Med, 2007, 176(8): 753-760.
|
2 |
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
|
3 |
Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study[J]. Lancet Respir Med, 2018, 6(6): 421-430.
|
4 |
World Health Organization. Global tuberculosis report 2018[R]. Geneva: WHO, 2018.
|
5 |
Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. (2020).
URL
|
6 |
国家卫生健康委,《中国结核病预防控制工作技术规范(2020年版)》,2020.4.2.
|
7 |
任成山,王关嵩,钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
|
8 |
陈华萍,胡明冬,张君国,等. 慢性阻塞性肺疾病合并症及其对预后的影响[J]. 解放军医学杂志,2020, 45(8): 834-839.
|
9 |
Elise G, George MI, Céline N, et al. Chronic obstructive pulmonary disease (COPD): neutrophils, macrophages and lymphocytes in patients with anterior tuberculosis compared to tobacco related COPD[J]. BMC Res Notes,2018, 11(1): 192.
|
10 |
Jardim Jr, Stirbulov R, Moreno D, et al. Respiratory medication use in primary careamong COPD subjects in four Latin American countries[J]. Int J Tuberc Lung Dis, 2017, 21(4): 458-465.
|
11 |
Pouldar D, Elsensohn A, Ortenzio F, et al. Nodular vasculitis in a patient with Crohn′s disease on vedolizumab[J]. Am J Dermatopathol, 2018, 40(3): 36-37.
|
12 |
Lin JT, Xing B, Tang HP, et al. A multi-center retrospective study of clinical characteristics and hospitalization costs of patients hospitalized for asthma exacerbation in China during 2013-2014[J]. Chin J Tuber Respirat Dis, 2017, 40(11): 830-834.
|
13 |
Koul P, Dar H, Jan R, et al. Two-year mortality in survivors of acute exacerbations of chronic obstructive pulmonary disease: a North Indian study[J]. Lung India, 2017, 34(6): 511-516.
|
14 |
吕 和,王 政,王 婷,等. 非活动性肺结核并发慢性阻塞性肺疾病患者营养状况及营养风险分析[J]. 中国防痨杂志,2020, 42(12): 1310-1312.
|
15 |
Wei ML, Zhao YJ, Qian ZY, et al. Pneumonia caused by Mycobacterium tuberculosis[J]. Microbes Infect, 2020, 22(6): 278-284.
|
16 |
Choi BJ, Prasad A, Gulati R, et al. Coronary endothelial dysfunctipon in patients with early coronary artery disease is associated with the increase in intravascular lipid core plaque[J]. Eur Heart J, 2013, 34(27): 2047-2054.
|
17 |
Trostdorf F, Landgraf C, Kablau M, et al. Increased endothelial cell apoptosis in symptomatic high-grade carotid artery atenosis: preliminary data[J]. Eur J Vase Endovasc Surg, 2007, 33(1): 6568.
|
18 |
Roversi S, Roversi P. Coronary artery disease concomitant with chronic obstructive pulmonary disease[J]. Eur J Clin Invest, 2014, 44(1): 93-102.
|
19 |
Liang BM, Xu ZB. Association of chronic obstructive pulmonary disease with coronary artery disease[J]. Chin Med J, 2013, 126(17): 3205-3208.
|
20 |
Agarwal S, Rokadia H. Burden of cardiovascular disease in chronic obstructive pulmonary disease[J]. Am J Prev Med, 2014, 47(2): 105-114.
|
21 |
Ferri C. Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease[J]. High Blood Press Cardiovasc Prev, 2015, 22(2): 103-111.
|
22 |
石 菡. 老年慢性阻塞性肺疾病急性期合并肺结核感染的治疗方法及其疗效探讨[J]. 临床与病理杂志,2016, 36(10): 1634-1639.
|
23 |
Lee SJ, Lee HR, Lee TW, et al. Usefulness of neutrophil to lymphocyte ratio in patients with chronic obstructive pulmonary disease: a prospective observational study[J]. Korean J intern Med, 2016, 31(5): 891-898.
|
24 |
Zumla A, Chakaya J, Centis R, et al. Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies[J]. Lancet Respir Med, 2015, 3: 220-234.
|
25 |
Glaziou P, Floyd K, Raviglione MC. Global epidemiology of tuberculosis [J]. Semin Respir Crit Care Med, 2018, 39: 271-285.
|
26 |
Luo Y, Xue Ying, Mao LY, et al. Diagnostic value of T-SPOT.TB assay for tuberculous peritonitis: A Meta-analysis[J]. Front Med (Lausanne), 2020, 7: 585180.
|
27 |
Fei GJ, Zhang LF, Shu HJ. Values of different laboratory diagnostic approaches for tuberculous peritonitiss[J]. Acta Academiae Medicinae Sinica, 2018, 40(4): 534-538.
|
28 |
Zhou L, Shen S, He M, et al. T-SPOT.TB in the diagnosis of tuberculous peritonitis[J]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2013, 38(5): 526-531.
|
29 |
Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis[J]. J Clin Gastroenterol, 2006, 40(8): 705-710.
|
30 |
任成山,林 辉,杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3): 269-274.
|